| Objective: Neoadjuvant chemotherapy can improve the therapeuticeffect of patients with breasr cancer, but the cytotoxic effect ofchemotherapy also produce some degree of adverse reactions in thosepatients. The purpose of this paper is to study the predictors of differentpatients’ response to neoadjuvant chemotherapy,and find out whichgroup can get better outcomes after neoadjuvant chemotherapy, in orderto get a better guide of clinical tailored treatment.Methods: The study included252patients with breast cancer whoreceived neoadjuvant chemotherapy.We assessed the expression of ER,PR, HER-2and Ki-67of those patients before neoadjuvant chemotherapy.The pathology response and disease free survival and overall survivalwere tested for all patients after surgery.Results: The results show that patients with negative ER or PR weremore likely to achieve pathologic complete response (pCR), P <0.001. Atthe same time, patients with hinger Ki-67(≥25%) were more likely toachieve pCR (P<0.05). HER-2status and different molecular subtype are not able to predict the response to neoadjuvant chemotherapy (P>0.05).After the patient’s disease-free survival and overall survival wereanalyzed, the results indicate that PR-positive patients get better overallsurvival compared with PR-negative patients (P <0.05). ER,Ki-67,Her-2status and different molecular subtype are not able to predictdisease-free survival or overall survival (P>0.05).Conclusion: To sum up, ER and PR negativity are associated withpCR after neoadjuvant chemotherapy. PR-positive patients got betteroverall survival although they achieve pCR less than PR-negtive ones. |
PDF Full Text Request